Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 15;29:42. doi: 10.1186/s12929-022-00824-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — miR-485-5p suppresses KRT17 expression and sphere formation and its effect on drug sensitivity of OSCC. A qPCR and immunoblotting were used to assess targeting effects of miR-485-5p on KRT17 mRNA (top panel) and protein (bottom panel) expression in C9IV3 and HSC3 cells in comparison with the miR-Con. B Sequence alignment of miR-485-5p binding site within the KRT17 3′-UTR (top panel). Luciferase activity assays from C9IV3 and HSC3 cells transfected with wild-type (WT) or mutant (MT) KRT17 3′-UTR reporter constructs in the presence of miRNA control (miR-Con) or miR-485-5p expression plasmids (bottom panel). C Sphere-formation assays using C9IV3 and HSC3 cells transfected with miR-Con, miR-485-5p or miR-485-5p + O-KRT17 (left panel). Quantitative analysis on the number of spheres formed is shown in the right panel. D Dose-dependent cellular growth assays using C9IV3 or HSC3 cells transfected with miR-Con, miR-485-5p or miR-485-5p + O-KRT17 plasmid in combination of treatment with cisplatin (0–100 μM) or carboplatin (0–250 μM). Data are presented as the mean ± SD (*p < 0.05, **p < 0.01 and ***p < 0.001). E Correlation analysis between miR-485-5p and KRT17 RNA levels in 24 OSCC tumor specimens from Kaohsiung Medical University, Taiwan